sepetaprost
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jul 25, 2017 (NCT03216902)
Timeline
Indications
Mechanism of action
- Prostanoid FP receptorAGONIST
PTGFR agonist
- Prostanoid EP3 receptorAGONIST
PTGER3 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)OC(=O)CCC[C@H]1CC[C@@H]2[C@@H](/C=C/[C@@H](O)COc3cc(F)ccc3F)[C@H](O)C[C@@H]2OC1- Mol. weight
- 482.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL4297633 ↗
Also known as
- sepetaprost
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05905653 | Phase 1 | May 25, 2023 | Santen Inc. |
| NCT05495061 | Phase 3 | Aug 9, 2022 | Santen Inc. |
| NCT05503901 | Phase 3 | Aug 8, 2022 | Santen Inc. |
| NCT03216902 | Phase 2 | Jul 25, 2017 | Santen Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Santen Inc. | For profit | 4 | 4 | 3 | 2017 |
1 organizations
Page 1 / 1